Form 8-K - Current report:
SEC Accession No. 0000950170-24-125927
Filing Date
2024-11-13
Accepted
2024-11-13 07:05:10
Documents
13
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fulc-20241113.htm   iXBRL 8-K 39621
2 EX-99.1 fulc-ex99_1.htm EX-99.1 111808
3 GRAPHIC img189780767_0.jpg GRAPHIC 18676
  Complete submission text file 0000950170-24-125927.txt   305044

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20241113.xsd EX-101.SCH 25999
15 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20241113_htm.xml XML 4925
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 241451137
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)